Loading
A phase 3 trial of Cisplatin and Nivolumab in oesophageal cancer, run by Shandong Boan Biotechnology Co., Ltd, now recruiting.
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06022861 by Shandong Boan Biotechnology Co., Ltd, with 510 participants planned, started 2023-10-12 and due to reach its primary completion in 2025-06. Interventions recorded: LY01015, Fluorouracil, Cisplatin and Opdivo®.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/